Skip to main content

Table 3 Characteristics of HBsAg-positive patients with hepatic dysfunction and without hepatic dysfunction during chemotherapy

From: Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma

 

Patients with hepatic dysfunction (No = 40) (49.4%)

Patients without hepatic dysfunction (No = 41) (50.6%)

p-value

Sex

  

0.22

Male

23(57.5)

18(43.9)

 

Female

17(42.5)

23(56.1)

 

Age (years)

  

0.096

≤ 60

28(70)

35(85.4)

 

> 60

12(30)

6(14.6)

 

Staging

  

0.088

I/II

13(32.5)

21(51.2)

 

III/IV

27(67.5)

20(48.8)

 

B symptom

  

0.43

Positive

15(37.5)

12(29.3)

 

Negative

25(62.5)

29(70.7)

 

PS

  

0.41

0,1

38(95)

37(90.2)

 

2,3,4

2(5)

4(9.8)

 

LDH

  

0.75

≤ Normal value

22(55)

24(58.5)

 

> Normal value

18(45)

17(41.5)

 

Extranodal sites

  

0.42

0–1

34(85)

32(78)

 

> 1

6(15)

9(22)

 

Liver involvement

  

0.63

Yes

7(17.5)

5(12.2)

 

No

33(82.5)

36(87.8)

 

Spleen involvement

  

0.50

Yes

12(30)

11(26.8)

 

No

28(70)

30(73.2)

 

HBV status prior to CT

  

0.38

HBsAg(+), HBeAg(+), Anti-HBc(+)

11(27.5)

15(36.6)

 

HBsAg(+), Anti-HBe(+), Anti-HBc(+)

29(72.5)

26(63.4)

 

Liver dysfunction prior to CT

  

0.38

Yes

10(25)

7(17.1)

 

No

30(75)

34(82.9)

 

Radiation

  

0.037

Yes

8(20)

17(41.5)

 

No

32(80)

24(58.5)

 

Chemotherapy

  

0.90

No. Range

2–20

1–13

 

Median

6

6

 

Response to front-line chemotherapy

  

0.26

CR

18(45)

25(61)

 

PR

19(47.5)

12(29.3)

 

SD

1(2.5)

3(7.3)

 

PD

2(5)

1(2.4)

Â